Perspectives

High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial. Christopher J. Logothetis and Paul F. Schellhammer ................................................................. 151

Targeting Transcription Factors for Cancer Prevention—the Case of Nrf2. Nancy H. Colburn and Thomas W. Kensler ......................................................................................... 153

Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops. Adi F. Gazdar and John D. Minna ........................................... 156

Commentary


Research Articles


Estimating Rates of True High-Grade Disease in the Prostate Cancer Prevention Trial. Paul Pinsky, Howard Parnes and Leslie Ford ........................................................................ 182

Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated Colorectal Cancer. Tin Oo Khor, Mou-Tuan Huang, Auemduan Prawan, Yue Liu, Xingpei Hao, Siwang Yu, William Ka Lung Cheung, Jefferson Y. Chan, Bandaru S. Reddy, Chung S. Yang and Ah-Ng Kong ........................ 187

Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. Ximing Tang, Marileila Varella-Garcia, Ana Carolina Xavier, Erminia Massarelli, Natalie Ozburn, Cesar Moran and Ignacio I. Wistuba ......................................................... 192


Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor–Selective Retinoid. Powel H. Brown, Kotha Subbaramaiah, Amoi P. Salmon, Rebecca Baker, Robert A. Newman, Peiyi Yang, Xi Kathy Zhou, Reid P. Bissonnette, Andrew J. Dannenberg and Louise R. Howe .................................................................................................................. 208
Letters to the Editor

Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial”. Richard G. Stevens, Theresa P. Pretlow, D. Paul Hurlstone and Charles Giardina ..................................215

Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial”. Peter Lance and Stanley R. Hamilton ..................................................................................................216

Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial”. Ann G. Zauber and Monica M. Bertagnolli for the APC Trial Investigators..................................................216

About the Cover

The cover images of H&E prostate tissue sections illustrate the potential variance between definitive prostatectomy scoring and nondefinitive biopsy scoring of prostate cancer in the Prostate Cancer Prevention Trial (PCPT). The two prostatectomy tissue sections (from the same patient) showed clinically “significant” cancer (Gleason score 7 [3+4], plus two foci at 6 [3+3]), whereas the corresponding diagnostic needle biopsy suggested clinically “insignificant” cancer of Gleason score 6 (3+3). Specimens came from a PCPT participant with a PSA of 2.1 ng/ml and stage T1c prostate cancer. See article by Lucia et al. on page 167 for more information (featured in The New York Times on June 15, 2008). Graphic design courtesy of Lisa Litzenberger. Also shown is a graph (lower left inset) illustrating the relative risk of high-grade disease with finasteride in the PCPT under various values of biopsy sensitivity for detecting cancer and incorporating PCPT prostatectomy data to account for the greater grading accuracy of biopsy with finasteride. In the orange-shaded region, all values of finasteride and placebo biopsy sensitivity reduce the risk of high-grade cancer; in the unshaded region, the 95% confidence intervals around the relative risk estimates include 1. The bold blue line represents the estimated reduction in high-grade risk given equal biopsy sensitivities for placebo and finasteride. See article by Redman et al. on page 174 for more information (featured in The New York Times on June 15, 2008).